David Cardona Müller

Dr. David Cardona Müller

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2019 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
JCJ. Carmona-Huerta
J. Carmona-Huerta
SOS. Castiello-De Obeso
S. Castiello-De Obeso
JRJ. Ramírez-Palomino
J. Ramírez-Palomino
RDR. Duran-Gutiérrez
R. Duran-Gutiérrez
DMDavid Cardona Müller
David Cardona Müller
RMR. Medina-Dávalos
R. Medina-Dávalos
Polypharmacy increases the risk of pharmacological interactions, prevalence of secondary effects and with this the lack of adherence to treatment. It is estimated that between 10 and 40% of patients hospitalized in psychiatric institutions are prescribed more than one antipsychotic. The objective of the present study was to identify the prevalence of polypharmacy, evaluate adverse effects associated to the use of psych drugs and to estimate the risk in specific groups. We carried out a longitudinal, retrospective study that included the analysis of all discharged patients (n = 140) in the first trimester of the year in a psychiatric hospital in Mexico. The information was classified into 7 sections: sociodemographic, diagnosis, clinical follow-up information, prescribed drugs, adverse reactions, substance abuse, laboratory and complementary results. Risk estimation was obtained with Odds Ratios, to correlate continuous variables Pearson’s correlation was used. Student’s T and Mann Whitney’s U were used to compare 2 independent samples; multiple and linear regressions were carried out. The mean number of drugs used during hospitalization was 7.8 drugs per patient. The mean prescribed psych drugs was 4.07. The mean antipsychotic dose was the risperidone equivalent of 5.08 mg. 29.2% of patients had at least one secondary effect associated to the use of drugs, 17.8% presented extrapyramidal symptoms. 81.4% of patients were prescribed 6 or more drugs (polypharmacy) and were 5 times more likely to suffer a secondary effects (OR 6.24). 14.2% had polypharmacy while receiving antipsychotics and had more than twice the risk of presenting extrapyramidal symptoms (OR 3.05). For each added psych drug, hospital stay increased by 6.56 days. Despite international guideline recommendations where reasoned and conciliatory prescription of psych drugs is advised, there is still a high prevalence of polypharmacy in patients hospitalized in psychiatric institutions. In the present study 4 out of 5 patients received polypharmacy decreasing tolerability, treatment adherence and increasing the risk and costs secondary to an increased hospital stay.

5 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMónica Vázquez-Del Mercado
Mónica Vázquez-Del Mercado
FPFelipe de J. Perez-Vazquez
Felipe de J. Perez-Vazquez
EGEduardo Gomez-Bañuelos
Eduardo Gomez-Bañuelos
ECEfrain Chavarria-Avila
Efrain Chavarria-Avila
ALArcelia Llamas-García
Arcelia Llamas-García
ECErnesto G. Cardona-Muñoz
Ernesto G. Cardona-Muñoz
It is well known that cardiovascular diseases (CVD) are a major contributor of death in systemic lupus erythematosus (SLE) as well in other rheumatic illness. In the last decades, there has been a growing development of different methodologies with the purpose of early detection of CVD. Objective: The aim of this study is to correlate the usefulness of subclinical parameters of vascular aging and QRISK 3–2017 score for early detection of CVD in SLE. Methods: Clinical assessment including systemic lupus erythematosus disease activity index (SLEDAI) and systemic lupus international collaborating clinics / american college of rheumatology damage index (SLICC/ACR DI), laboratory measurements, carotid ultrasound examination, carotid intima media thickness (cIMT) measurement, carotid distention and diameter analysis, arterial stiffness measurement measured by tonometry and QRISK 3–2017 were done. All results were analyzed by SPSS 24 software. Results: We observed correlation between QRISK3 and mean cIMT (rs = 0.534, P < 0.001), PWV (rs = 0.474, P < 0.001), cfPWV (rs = 0.569, P < 0.001) and distensibility (rs = -0.420, P = 0.006). Consistent with above, SLE patients in middle and high risk QRISK 3–2017 showed increased arterial stiffness versus low risk group. Conclusions: We encourage to the rheumatology community to assess cardiovascular risk in SLE patients with QRISK 3–2017 risk calculator as an alternative method at the outpatient clinic along a complete cardiovascular evaluation when appropriate.

11 January 2021 in International Journal of Mental Health Systems
Verified
Journal Article
Open access
PDF file
JCJaime Carmona-Huerta
Jaime Carmona-Huerta
SDSol Durand-Arias
Sol Durand-Arias
ARAllen Rodriguez
Allen Rodriguez
CGCarmen Guarner-Catalá
Carmen Guarner-Catalá
DMDavid Cardona Müller
David Cardona Müller
RARubén Alvarado
Rubén Alvarado
Background: Access to mental health care is a worldwide public health challenge. In Mexico, an unacceptably high percentage of the population with mental disorders does not receive the necessary treatment, which is mainly due to the lack of access to mental health care. The community mental health care model was created and has been implemented to improve this situation. In order to properly plan and implement this model a precise situational diagnosis of the mental health care network is required, thus this is a first approach to evaluate the community mental health networks in the state of Jalisco. Methods: Two components from the EvaRedCom–TMS instrument were used including a general description and accessibility of the community mental health care network. A geographic and economic accessibility evaluation was carried out for the different regions of the state ranging from scattered rural to urban communities using information gathered from health institutions, telephone interviews and computer applications. Results: Jalisco’s community mental health network includes a total of 31 centers and 0.64 mental health workers for every 10,000 inhabitants > 15 years of age. The mean transportation cost required to access mental health care was 16.25 USD per visit. The time needed to reach the closest mental health center in 7 of the 13 analyzed regions was more than 30 min and the mean time required to reach a prolonged stay center was 172.7 min with transportation cost (taxi, private and public transport) of 22.3 USD. Some marginalized regions in the state have a mean 114 min required to reach the closest mental health care center and 386 min to reach a prolonged stay center. Conclusions: This first approach to evaluate the mental health networks in Mexico showed that there are multiple barriers to access its care including an unfavorable number of human resources, long distances, and high costs. The identification of Jalisco’s mental health network deficiencies is the first step towards establishing a properly planned community mental health care model within the country.
1

1 January 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
MRMelissa Ramirez-Villafaña
Melissa Ramirez-Villafaña
ASAna M Saldaña-Cruz
Ana M Saldaña-Cruz
JAJavier A Aceves-Aceves
Javier A Aceves-Aceves
Edsaul Emilio Perez-GuerreroEdsaul Emilio Perez-Guerrero
Edsaul Emilio Perez-Guerrero
NFNicte Selene Nicte Selene Fajardo-Robledo
Nicte Selene Nicte Selene Fajardo-Robledo
LLLaura Gonzalez Lopez
Laura Gonzalez Lopez
Background . Neuropeptide Y (NPY) is a sympathetic neurotransmitter with effects on the regulation of inflammatory cells. The role of NPY on autoimmune inflammatory diseases such as rheumatoid arthritis (RA) is not completely understood. Therefore, we evaluate if NPY levels are markers of disease activity in RA and if there is a correlation between NPY levels and tumor necrosis factor‐alpha (TNF‐ α ), leptin, and interleukin 6 (IL‐6) levels. Methods . Cross‐sectional design, including 108 women with RA. We assessed disease activity by DAS28‐ESR (considering active disease a score of ≥2.6). Serum NPY levels and anti‐CCP2 antibody, TNF‐ α , IL‐6, and leptin levels were quantified (ELISA). Results . Sixty‐eight RA had an active disease (RA‐active), and 40 were in remission (RA‐remission). RA‐active patients had higher NPY levels vs. RA‐remission (22.8 ± 13.6 vs. 17.8 ± 10.3; p = 0.04). NPY levels correlated with increased TNF‐ α levels ( r = 0.32, p = 0.001). Leptin or IL‐6 did not correlate with NPY levels. In the logistic regression analysis, NPY increased the risk of disease activity (OR: 1.04, 95% CI 1.006‐1.09, and p = 0.03). Conclusion . Higher NPY levels are an independent marker of disease activity in RA. This study encourages the quantification of NPY levels as a surrogate marker for RA‐active. Future studies evaluating the role of NPY levels interacting with other proinflammatory cytokines are required.

3 April 2019 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
DPDulman O. Pineda-De Paz
Dulman O. Pineda-De Paz
Jorge Eduardo Hernandez del RioJorge Eduardo Hernandez del Rio
Jorge Eduardo Hernandez del Rio
CPCHRISTIAN GONZALEZ PADILLA
CHRISTIAN GONZALEZ PADILLA
RERamón M. Esturau-Santaló
Ramón M. Esturau-Santaló
JRJoseph Romero-Palafox
Joseph Romero-Palafox
DMDavid Cardona Müller
David Cardona Müller
There are three major mechanical complications after acute myocardial infarction: left ventricular free-wall rupture, ventricular septum rupture and acute mitral valve regurgitation. The left ventricular free-wall rupture is a serious and often lethal complication following an ST elevation myocardial infarction. However, very rarely this rupture can be contained by the pericardium, forming a pseudoaneurysm. We report a case of a 66-year-old man with multiple cardiovascular risk factors and previous ST elevation myocardial infarction, complaining of atypical chest pain. His electrocardiogram was in normal sinus rhythm, with the presence of Q wave in inferior leads and T-wave inversion in lateral leads. A transthoracic echocardiogram showed a left ventricular pseudoaneurysm. In the coronary angiography, multi-vessel disease was found. On-pump CABG was performed and a posterolateral left ventricular giant pseudoaneurysm were observed. Due its “petrous” consistency it was impossible to perform an aneurysmectomy. The diagnosis of left ventricular pseudoaneurysm can be difficult, as patients often present either asymptomatic or with non-specific symptoms attributed to other causes. A multimodality imaging diagnostic approach can be necessary. Immediate surgery is considered the treatment of choice because untreated pseudoaneurysms have a high risk of rupture leading to cardiac tamponade, shock and death.

18 May 2025 in Life
Verified
Journal Article
Open access
ECErick González Campos
Erick González Campos
FGFernando Grover-Páez
Fernando Grover-Páez
CBCarlos Gerardo Ramos Becerra
Carlos Gerardo Ramos Becerra
LALuis Ricardo Balleza Alejandri
Luis Ricardo Balleza Alejandri
Daniel Osmar Suárez-RicoDaniel Osmar Suárez-Rico
Daniel Osmar Suárez-Rico
DMDavid Cardona Müller
David Cardona Müller
(1) Background: Arterial stiffness, often measured by carotid–femoral pulse wave velocity (cf-PWV), is crucial in cardiovascular disease. Dapagliflozin has shown rapid effects on arterial stiffness, but there is limited evidence of empagliflozin’s acute effects, especially in type 2 diabetes (T2D) patients. This study evaluated the acute effects of empagliflozin and dapagliflozin on arterial stiffness and blood pressure (BP). (2) Methods: A one-week double-blind randomized trial involved 30 T2D patients on stable metformin therapy. Participants received empagliflozin (25 mg/day), dapagliflozin (10 mg/day), or a placebo. Arterial stiffness was assessed via cf-PWV, and BP was measured with an automated sphygmomanometer. (3) Results: Both SGLT2 inhibitors significantly reduced cf-PWV compared to the placebo after one week (p < 0.05), with dapagliflozin showing a more pronounced effect. No significant differences were observed in BP changes. (4) Conclusion: Short-term treatment with SGLT2 inhibitors acutely reduces arterial stiffness in T2D patients, with empagliflozin demonstrating a stronger effect, supporting the potential vascular benefits of SGLT2 inhibitors beyond glucose control.